Leslie A. Washburn

Abstract 7935: Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial

Lionel Aurelien Kankeu Fonkoua, Christopher L. Hallemeier, Basim Salem, Arina V. Tkachuk et autres

Abstract Background: Hepatocellular carcinoma (HCC) is largely refractory to immune checkpoint blockade due to immune exclusion, stromal barriers, and aberrant vasculature. We evaluated whether multimodal therapy - external beam radiotherapy (EBRT) for antigen release, intratumoral dendritic cell (DC) vaccination for antigen presentation, …

us (code pays fourni par la source)

Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.

Nguyen H. Tran, Jacob Hirdler, Ajith Antony, Jacob J. Teske et autres

Abstract Prostate-specific membrane antigen (PSMA) is highly expressed in tumor-associated neovasculature in hepatocellular carcinoma (HCC), highlighting its promise as a theranostic target. This prospective study aimed to evaluate the utility of novel biomarkers derived from PSMA positron emission tomography computed tomography (PET/CT) …

us (code pays fourni par la source)

A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).

Wen Wee Ma, Garth Nelson, Nguyen H. Tran, Oxana Crysler et autres

554 Background: Atezo/Bev is the 1 st -line standard for advanced hepatocellular carcinoma (aHCC). Optimal 2 nd -line therapy post-Atezo/Bev remains undefined. This study evaluates continuation of atezolizumab with a MKI versus MKI alone in the 2 nd -line setting. Methods: This …

us (code pays fourni par la source)

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

Ioannis A. Kournoutas, Paulina S. Marell, Jennifer Jane Gile, Anina Peersen et autres

BACKGROUND: Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. METHODS: We reviewed outcomes of patients with uHCC who initiated atezo/bev or …

us (code pays fourni par la source)

Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience

Paulina S. Marell, Ioannis A. Kournoutas, Jennifer Jane Gile, Anina Peersen et autres

BACKGROUND: Atezolizumab plus bevacizumab (A/B) received FDA approval as the first-line therapy for patients with advanced hepatocellular carcinoma (HCC) in 2020. However, optimal subsequent treatment options are unclear. Here, we describe clinical outcomes of advanced HCC patients following first-line treatment with A/B. …

us (code pays fourni par la source)

Prognostication of ß-catenin (CTNNB1) in patients with HCC treated with first line immunotherapy.

Priyanshi M. Shah, Anina Peersen, Aminah Jatoi, Robert R. McWilliams et autres

e15146 Background: Wnt/ß-catenin signaling dysregulation is found in approximately 25% of hepatocellular carcinoma (HCC) patients. The impact of B-catenin activation on HCC overall survival has remained controversial. Prior studies suggest activating CTNNB1 mutations may predict for immunotherapy (IO) resistance while others did …

us (code pays fourni par la source)

Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review

Leslie A. Washburn, Amit Mahipal, Aminah Jatoi, Lisa A. Kottschade et autres

Background: Cholangiocarcinoma during postpartum or pregnancy is a rare presentation. There are limited cases reported in the literature. Diagnosis can be delayed as presenting signs and symptoms may be attributed to pregnancy or postpartum state. Case Description: We present the case of …

us (code pays fourni par la source)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

Sri Harsha Tella, Nathan R. Foster, Qian Shi, Tran Nguyen et autres

BACKGROUND: We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). METHODS: A total of 28 patients (27 were evaluable) with advanced BTCs who …

us (code pays fourni par la source)

CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)

Sri Harsha Tella, Jaclynn Wessling, Foster Nathan, Tran Nguyen et autres

us (code pays fourni par la source)

CME Chronic lymphocytic leukemia Chronic lymphocytic leukemia: The most common leukemia in adults

Leslie A. Washburn

Primary care PAs may not treat CLL, but they do need to understand the disease and its complications since most patients with CLL will eventually require therapy.

us, my (code pays fourni par la source)

Nutrient Utilization by “Compact” and Conventional Type Shorthorn Steers

Leslie A. Washburn, Johnny Matsushima, Herman F. Pearson, R. C. Tom

Nutrient utilization by Shorthorn steers of “compact” and conventional types was investigated by means of digestion balance trials and analysis of standard carcass cuts following slaughter. Limited data of a preliminary nature showed no appreciable difference between steer types with respect to …

Potatoes for cattle fattening

W. E. Connell, Leslie A. Washburn, R. C. Tom, E. M. Mervine et autres